NASDAQ:BBLG
Bone Biologics Corp
Bone Biologics Corp reported net income of −$3.1M in fiscal 2025. The diluted share count rose 364.4%.Summary generated from Bone Biologics Corp's SEC filings. Latest annual report filed Mar 2, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−70.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+364.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −1 | −4 | −9 | −4 | −3 |
| Net income | −2 | −1 | −9 | −4 | −3 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 30, 2026 - 4Insider transaction report
Sep 30, 2026 - 8-KResults of a shareholder vote
Sep 29, 2026 - 8-KNotice of delisting or listing-rule failure
Sep 16, 2026 - DEF 14AProxy statement
Aug 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KRegulation FD disclosure
Jul 23, 2026 - 8-KOther events
Jul 16, 2026